
    
      Patients are randomly assigned to the empirical therapy group and tailored therapy group.

      The empirical therapy group recieves triple therapy of 7 or 14 days. The tailored therapy
      group receives treatment based on their DPO-PCR results.

      Patients who are sensitive to clarithromycin based on DPO-PCR receives triple therapy for 7
      or 14 days. Patients who are resistant to clarithromycin based on DPO-PCR recieves bismuth
      quadruple therapy for 7 or 14 days.
    
  